相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。GLORYx: Prediction of the Metabolites Resulting from Phase 1 and Phase 2 Biotransformations of Xenobiotics
Christina de Bruyn Kops et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2021)
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold
Min Sun et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Exploring protein phosphorylation by combining computational approaches and biochemical methods
Gonzalo Perez-Mejias et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors
Bingbing Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
The test that changed the world: The Ames test and the regulation of chemicals
Errol Zeiger
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2019)
Target Dose Versus Maximum Tolerated Dose in Heart Failure Time to Calibrate and Define Actionable Goals
Biykem Bozkurt
JACC-HEART FAILURE (2019)
Why maximum tolerated dose?
Hans G. Stampfer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
FAME 3: Predicting the Sites of Metabolism in Synthetic Compounds and Natural Products for Phase 1 and Phase 2 Metabolic Enzymes
Martin Sicho et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)
Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome
Hongwei Cheng et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Resolving the Mystery of Ring Opening in the Synthesis of Benzo[d][1,3]oxazin-4-one and Quinazolin-4(3H)-one
Harun Patel et al.
LETTERS IN ORGANIC CHEMISTRY (2019)
Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K
Jia Yin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Molecular and cellular physiology of organic cation transporter 2
Stephen H. Wright
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
Harun Patel et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2018)
Derivation of avian dermal LD50 values for dermal exposure models using in vitro percutaneous absorption of [14C]-atrazine through rat, mallard, and northern bobwhite full thickness skin
Jonathan D. Maul et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2018)
Structural and functional aspects of P-glycoprotein and its inhibitors
Shirin Mollazadeh et al.
LIFE SCIENCES (2018)
Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFRα1 and Small-Molecule Ligands
Larisa Ivanova et al.
ACS OMEGA (2018)
Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors
Harun Patel et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2018)
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
Harun Patel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle
Harun M. Patel et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy
Sol-Bi Shin et al.
ANTICANCER RESEARCH (2017)
The Micro-Ames Test: A Direct Comparison of the Performance and Sensitivities of the Standard and 24-Well Plate Versions of the Bacterial Mutation Test
Raymond Proudlockand et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2016)
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer
Zhendong Song et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Anti-convulsant potential of quinazolinones
Harun M. Patel et al.
RSC ADVANCES (2016)
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Harun M. Patel et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2015)
Volume of Distribution in Drug Design
Dennis A. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
Douglas E. V. Pires et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands
Dora Toledo Warshaviak et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring
Kai Zhu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors
Samar Mowafy et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints
Xuchang Ouyang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2013)
Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach
Malleshappa N. Noolvi et al.
ARABIAN JOURNAL OF CHEMISTRY (2013)
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
H. Murakami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Youngwook Kim et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Drug-permeability and transporter assays in Caco-2 and MDCK cell lines
Donna A. Volpe
FUTURE MEDICINAL CHEMISTRY (2011)
Chronic oral LOAEL prediction by using a commercially available computational QSAR tool
Bernd Rupp et al.
ARCHIVES OF TOXICOLOGY (2010)
Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Martin L. Sos et al.
CANCER RESEARCH (2010)
Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
Akihiko Kawahara et al.
CLINICAL CANCER RESEARCH (2010)
Targeted covalent drugs of the kinase family
Juswinder Singh et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
Shu-Feng Zhou
CURRENT DRUG METABOLISM (2008)
Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
Allan R. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes
Richard A. Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel
JM Ridley et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Plasma clearance
PL Toutain et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2004)
Role of P-glycoprotein in pharmacokinetics - Clinical implications
JH Lin et al.
CLINICAL PHARMACOKINETICS (2003)
Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
AJ Barker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
分享论文
